Core Viewpoint - The procurement of Tianjin Weiming's interferon α2b spray has been suspended in certain regions due to non-compliance with biological activity standards, following inspections by regulatory authorities [2][3]. Group 1: Company Overview - Tianjin Weiming Biopharmaceutical Co., Ltd. is a subsidiary of Weiming Pharmaceutical (002581.SZ), holding approximately 60% of its shares [3]. - The interferon α2b spray generated approximately 229 million yuan in revenue in 2022, accounting for 64.27% of Weiming Pharmaceutical's total revenue for that year [3]. - The product was awarded a procurement price of 33.58 yuan per bottle, effective from June 1, 2024, as part of a collective procurement initiative involving 29 provinces [3]. Group 2: Financial Performance - In the first half of 2024, Tianjin Weiming reported revenue of approximately 142 million yuan and a net profit of about 12.73 million yuan [5]. - Weiming Pharmaceutical's revenue for the same period was around 210 million yuan, with a loss of 29.62 million yuan [5]. - The company anticipates a revenue range of 360 million to 400 million yuan for 2024, with expected losses between 95 million and 155 million yuan [5]. Group 3: Market Impact and Product Significance - The interferon α2b spray is noted as the world's first interferon spray, filling a gap in the antiviral field in China [5]. - The product has been on the market for nearly 20 years, with its safety and efficacy validated through clinical studies [5]. - The collective procurement is expected to reduce patients' medical expenses significantly and enhance the accessibility of the medication [5].
抽检结果不过关 未名医药核心产品被多地暂停采购